Abstract
The risk of hematologic malignancies was studied in Finnish patients withrheumatoid arthritis or Sjögren's syndrome, and the difference in the riskbetween those diseases was evaluated. The study cohorts comprised 676patients with primary Sjögren's syndrome, 709 with secondary Sjögren'ssyndrome, and 9,469 with rheumatoid arthritis identified from the Finnishhospitals' national discharge register. The follow-up times were 5,336, 4,254and 65,391 person-years, respectively. Data on the incidence of malignancieswere collected from the files of the Finnish Cancer Registry. The incidenceof hematologic malignancies was elevated in the study cohorts. Thestandardized incidence ratio (SIR) of non-Hodgkin's lymphoma was: 2.2 (95percent confidence interval [CI] 1.5-3.1) for rheumatoid arthritis; 4.5 (CI =1.5-11) for secondary Sjögren's syndrome; and 8.7 (CI = 4.3-16) for primarySjögren's syndrome. The ratio of the SIR of primary Sjögren's syndroma cfrheumatoid arthritis alone was 3.9 (CI = 1.8-8.0) in non-Hodgkin's lymphoma,and 3.4 (CI = 1.2-8.1) in other hematologic cancers. The incidence ofhematologic malignancies, especially that of non-Hodgkin's lymphoma, iselevated in patients with rheumatoid arthritis. It is higher in patients withsecondary Sjögren's syndrome and highest in patients with primary Sjögren'ssyndrome. Differences in the immuno-logic aberration influenceoncogenesis.
Similar content being viewed by others
References
Santana V, Rose NR. Neoplastic lymphoproliferation in autoimmune disease: An updated review. Clin Immunol Immunopathol 1992; 63: 205–13.
Holm LE, Blomgren H, Löwhagen T. Cancer risk in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985; 312: 601–4.
Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Int Med 1978; 89: 888–92.
Isomäki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978; 31: 691–6.
Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. JNCI 1993; 85: 307–11.
Silman AJ, Petrie J, Hazleman B, Evans SJW. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann Rheum Dis 1988; 47: 988–92.
Tennis P, Andrews E, Bombardier C, et al. Record linkage to conduct an epidemiological study on the association of rheumatoid arthritis and lymphoma in the province of Saskatchewan, Canada. J Clin Epidemiol 1993; 46: 685–95.
Abbatt JD, Lea AJ. Leukaemogens. Lancet 1958; 2: 880–3.
Gridley G, Klippel JH, Hoover RN, Fraumeni JF Jr. Incidence of cancer among men with the Felty syndrome. Ann Intern Med 1994; 120: 35–9.
Plachecka M, Polowiec Z, Abgarowicz-Milkowska T, et al. Lymphoreticular proliferative syndromes in rheumatoid diseases. ' R '1977; 6: 575–82.
Eriksson M. Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer 1993; 29A: 259–63.
Ichikawa Y, Takaya M, Shimizu H, et al. Comparison of antinuclear antibody and other immunohematological profiles among primary Sjogren's syndrome, secondary Sjogren's syndrome associated with rheumatoid arthritis or systemic lupus erythematosus, and corresponding systemic disease. Tokai J Exp Clin Med 1993; 18: 133–8.
Prior P. Cancer and rheumatoid arthritis: epidemiological considerations. Am J Med 1985; 78(1A): 15–21.
Myllykangas-Luosujärvi R, Aho K, Isomäki H. Mortality from cancer in patients with rheumatoid arthritis. Scand J Rheumatol 1995; 24: 76–8.
Kamel OW, van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: Frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994; 25: 638–43.
Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW. Methotrexate-associated lymphoma in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 325–9.
Kalden JR, Winkler T, Krapf F. Are retroviruses involved in the aetiology of rheumatic diseases? Brit J Rheumatol 1991; 30: 63–9.
Kinlen L, Skeil A, Peto R, Doll R. Collaborative UK-Australasian study of cancer in patients treated with immunosuppressive drugs. Brit Med J 1979; 2: 1461–6.
Baltus J, Boersma J, Hartman A, Vandenbroucke J. Occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983; 42: 368–73.
Kauppi M, Savolainen HA, Anttila V-J, Isomäki HA. Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Paediatr 1996; 85: 248–50.
Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514–6.
Talal N, Bunim JJ. Development of malignant lymphoma in the course of Sjögren's syndrome. Am J Med 1964; 36: 529–40.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kauppi, M., Pukkala, E. & Isomäki, H. Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8, 201–204 (1997). https://doi.org/10.1023/A:1018472213872
Issue Date:
DOI: https://doi.org/10.1023/A:1018472213872